Savara Says FDA Will Not Meet PDUFA Target Action Date Of November 22 For Molgramostim Inhalation Solution BLA For Treatment Of Autoimmune PAP; No Revised Action Date Communicated By The FDA
Benzinga Newsdesk 16 hours ago
NewsFDA
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the
Savara Inc. (NASDAQ:SVRA), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated that it will not meet the Prescription Drug User Fee Act (PDUFA) target action date of November 22, 2026 for the Company’s molgramostim inhalation solution (molgramostim) Biologics License Application (BLA) for the treatment of autoimmune PAP. The review of the BLA is ongoing and no revised action date has been provided by the agency.
More on SVRA
FDA & biotech Benzinga
Savara Craters as FDA Delays Decision for Lung DiseaseSavara (NASDAQ: SVRA) shares fell Friday after the FDA said it will miss its November 22, 2026 PDUFA target date for molgramostim.

Analyst ratings Benzinga
HC Wainwright & Co. Maintains Buy on Savara, Lowers Price Target to $9HC Wainwright & Co. analyst Matthew Caufield maintains Savara (NASDAQ:SVRA) with a Buy and lowers the price target from $10 to $9.
